Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase plus IVIg in Guillain-Barré syndrome (phase II, open-label, single-arm)
2018-001059-12Phase 2Unknown
- Sponsor
- Hansa Biopharma
- Start
- Dec 2018
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imlifidase in Guillain-Barré syndrome (GBS), sponsored by Hansa Biopharma. Primary endpoint: Safety and tolerability (AEs/SAEs and clinical parameters). Status: unknown.
02
Drugs
imlifidase
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on 2018-001059-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001059-12.